Pasar al contenido principal

NUEVAS PERSPECTIVAS SOBRE LA PROGRESION DE LA LEUCEMIA LINFOCITICA CRONICA: NUEVAS FUNCIONES DE LA MMP-9 Y PAPEL DE LA INTERACCION CELULA LLC-MACROFAGO

SAF2015-69180-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest, Running title: Role of the MMP-9 target CD99 in CLL migration

  • Aguilera-Montilla, Noemí
  • Bailón, Elvira
  • Uceda-Castro, Rebeca
  • Ugarte-Berzal, Estefanía
  • Santos, Andrea
  • Gutiérrez-González, A.
  • Pérez-Sánchez, Cristina
  • Steen, Philippe E. Van den
  • Opdenakker, Ghislain
  • García-Marco, José A.
  • García-Pardo, Angeles
58 p.-8 fig.-6 tab. supl., We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces cell arrest. To further explore the latter function, we studied whether MMP-9 influences the gene-expression profile in CLL. Microarray analyses rendered 131 differentially expressed genes in MEC-1 cells stably transfected with MMP-9 (MMP-9-cells) versus cells transfected with empty vector (Mock-cells). Ten out of twelve selected genes were also differentially expressed in MEC-1 cells expressing the catalytically inactive MMP-9MutE mutant (MMP-9MutE-cells). Incubation of primary CLL cells with MMP-9 or MMP-9MutE also regulated gene and protein expression, including CD99, CD226, CD52, and CD274. Because CD99 is involved in leukocyte transendothelial migration, we selected CD99 for functional and mechanistic studies. The link between MMP-9 and CD99 was reinforced with MMP-9 gene silencing studies, which resulted in CD99 upregulation. CD99 gene silencing significantly reduced CLL cell adhesion, chemotaxis and transendothelial migration, while CD99 overexpression increased cell migration. Mechanistic analyses indicated that MMP-9 downregulated CD99 via binding to α4β1 integrin and subsequent inactivation of the Sp1 transcription factor. This MMP-9-induced mechanism is active in CLL lymphoid tissues, since CD99 expression and Sp1 phosphorylation was lower in bone marrow-derived CLL cells than in their peripheral blood counterparts. Our study establishes a new gene regulatory function for MMP-9 in CLL. It also identifies CD99 as an MMP-9 target and a novel contributor to CLL cell adhesion, migration and arrest. CD99 thus constitutes a new therapeutic target in CLL, complementary to MMP-9., This work was supported by Grant SAF2015-69180R and Red Temática de Investigación Cooperativa en Cáncer Grant RD12/0036/0061 from the Ministry of Economy and Competitivity (Spain) (to AGP); S2010/BMD-2314 (to AGP) from the Comunidad de Madrid/European Union; and by the Concerted Research Actions (KU Leuven C1 Grant C16/17/010) and the Research Foundation of Flanders (FWO-Vlaanderen, to EUB, PEVdS, and GO)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

α4β1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling

  • Gutiérrez-González, A.
  • Aguilera-Montilla, Noemí
  • Ugarte-Berzal, Estefanía
  • Bailón, Elvira
  • Cerro-Pardo, Isabel
  • Sánchez-Maroto, Clara
  • García-Campillo, Lara
  • García-Marco, José A.
  • García-Pardo, Angeles
5 p.-2 fig., In chronic lymphocytic leukemia (CLL), α4β1 integrin (the main α4 heterodimer in CLL) and vascular endothelial growth factor (VEGF) share several pathological properties, including involvement in cell migration and survival.Accordingly, elevated expression of α4 integrin (≥30% cells) constitutes an adverse prognostic marker and VEGF serum levels increase with CLL progression and could also have prognostic value. CLL cells express VEGF receptor 1 (VEGFR1), VEGFR2, and VEGFR3 receptors.VEGFR2 is the main signaling receptor in response to VEGF165 and its elevated expression correlates with CLL aggressivenes. Previous studies in endothelial cells have demonstrated interactions and functional cross talk between integrins (αvβ3, α9β1, α3β1, α5β1) and the VEGF/VEGFR2 system, including integrin-mediated adhesion to VEGF and VEGF-induced integrin activation.Moreover, shedding of syndecan-1 in endothelial cells induced coupling of α4β1 integrin and VEGFR2, VEGFR2 activation, and angiogenesis. It is not known whether α4β1 interacts with VEGF/VEGFR2 or/and contributes to VEGF functions in CLL and we have addressed this in the present study., This work was supported by grants SAF2015-69180R from the Ministry of Economy and Competitivity (Spain) and S2010/BMD-2314 from the Comunidad de Madrid/European Union (A.G.-P.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells

  • Aguilera-Montilla, Noemí
  • Bailón, Elvira
  • Ugarte-Berzal, Estefanía
  • Uceda-Castro, Rebeca
  • Prieto-Solano, María
  • García-Martínez, Elena
  • Samaniego, Rafael
  • Steen, Philippe E. Van den
  • Opdenakker, Ghislain
  • García-Marco, José A.
  • García-Pardo, Angeles
27 p.-3 fig.-2 tab., Increased angiogenesis is commonly observed in chronic lymphocytic leukemia (CLL) tissues in correlation with advanced disease. CLL cells express pro- and anti-angiogenic genes and acquire a pro-angiogenic pattern upon interaction with the microenvironment. Because MMP-9 (a microenvironment component) plays important roles in solid tumor angiogenesis, we have studied whether MMP-9 influenced the angiogenic pattern in CLL cells. Immunofluorescence analyses confirmed the presence of MMP-9 in CLL tissues. MMP-9 interaction with CLL cells increased their MMP-9 expression and secretion into the medium. Accordingly, the conditioned media of MMP-9-primed CLL cells significantly enhanced endothelial cell proliferation, compared to control cells. MMP-9 also increased VEGF and decreased TSP-1 and Ang-2 expression, all at the gene and protein level, inducing a pro-angiogenic pattern in CLL cells. Mechanistic analyses demonstrated that downregulation of the selected gene TSP-1 by MMP-9 involved α4β1 integrin, Src kinase family activity and the STAT3 transcription factor. Regulation of angiogenic genes is a novel contribution of MMP-9 to CLL pathology., This work was supported by grants SAF2015-69180R from the Ministerio de Economía y Competitividad (Spain)/Fondo Europeo de Desarrollo Regional (FEDER), European Union; S2010/BMD-2314 from the Comunidad de Madrid/European Union (AGP.); and by the Concerted Research Actions (KU Leuven C1 Grant C16/17/010) and the Research Foundation of Flanders (FWO-Vlaanderen, to EUB, PEVdS, and GO)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulation and function of angiogenic factors in chronic lymphocytic leukemia

  • García-Pardo, Angeles
  • Redondo-Muñoz, Javier
22 p.-1 fig.-2 tab., Progression of chronic lymphocytic leukemia (CLL) is determined by the localization of malignant cells in lymphoid tissues, where they receive growth and survival signals. CLL cells produce angiogenic factors that are regulated by internal and external stimuli and whose levels vary according to the clinical stage of the disease. Stromal cellular and molecular components in CLL niches disturb the balance of pro- and antiangiogenic molecules in CLL cells and induce an angiogenic switch. Additionally, CLL cells also influence the behavior of microenvironmental cells,inducing endothelial cell proliferation and increasing the angiogenic capacity of macrophages, neutrophils, and other cells present in CLL niches. As a result of these reciprocal functional interactions, bone marrow angiogenesis is frequently increased in CLL and has been proposed as a prognostic marker in early disease. Besides their role in regulating angiogenesis, angiogenic factors are also involved in CLL cell migration and survival, all contributing to disease progression. Angiogenic factors, particularly vascular endothelial growth factor, have therefore been attractive therapeutic targets in CLL and many clinical trials were established in the past years. However, the results of these trials reveal that anti-angiogenic therapies alone are not as efficient as expected and should rather be used in combination with other treatments., Work for the author’s laboratory was supported by grants SAF2009-07035, SAF2012-31613, SAF2015- 69180-R, PI060400, RD06/0020/0011, RD12/0036/0061 (to García-Pardo A) and SAF2017-86327-R (to Redondo-Muñoz J) from the Ministerio de Ciencia e Innovacion- Fondo Europeo de Desarrollo Regional (FEDER), Madrid; P2010/BMD-2314 from the Comunidad de Madrid/European Union (to García-Pardo A); the Fundación de Investigación Mutua Madrileña (to García-Pardo A); the 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation) (to Redondo-Muñoz J)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular players in hematologic tumor cell trafficking

  • Redondo-Muñoz, Javier
  • García-Pardo, Angeles
  • Teixidó, Joaquín
18 p.-3 fig., The trafficking of neoplastic cells represents a key process that contributes to progression of hematologic malignancies. Diapedesis of neoplastic cells across endothelium and perivascular cells is facilitated by adhesion molecules and chemokines, which act in concert to tightly regulate directional motility. Intravital microscopy provides spatio-temporal views of neoplastic cell trafficking, and is crucial for testing and developing therapies against hematologic cancers. Multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL) are hematologic malignancies characterized by continuous neoplastic cell trafficking during disease progression. A common feature of these neoplasias is the homing and infiltration of blood cancer cells into the bone marrow (BM), which favors growth and survival of the malignant cells. MM cells traffic between different BM niches and egress from BM at late disease stages. Besides the BM, CLL cells commonly home to lymph nodes (LNs) and spleen. Likewise, ALL cells also infiltrate extramedullary organs, such as the central nervous system, spleen, liver, and testicles. The α4β1 integrin and the chemokine receptor CXCR4 are key molecules for MM, ALL, and CLL cell trafficking into and out of the BM. In addition, the chemokine receptor CCR7 controls CLL cell homing to LNs, and CXCR4, CCR7, and CXCR3 contribute to ALL cell migration across endothelia and the blood brain barrier. Some of these receptors are used as diagnostic markers for relapse and survival in ALL patients, and their level of expression allows clinicians to choose the appropriate treatments. In CLL, elevated α4β1 expression is an established adverse prognostic marker, reinforcing its role in the disease expansion. Combining current chemotherapies with inhibitors of malignant cell trafficking could represent a useful therapy against these neoplasias. Moreover, immunotherapy using humanized antibodies, CAR-T cells, or immune check-point inhibitors together with agents targeting the migration of tumor cells could also restrict their survival. In this review, we provide a view of the molecular players that regulate the trafficking of neoplastic cells during development and progression of MM, CLL, and ALL, together with current therapies that target the malignant cells., Work from the author's laboratories was supported by grants SAF2014-53059-R and SAF2017-85146-R to JT; SAF2012-31613-R and SAF2015-69180-R to AG-P; RYC-2015-18497 and SAF2017-86327-R to JR-M from the Ministry of Economy and Competitivity. Also by grant P2010/BMD-2314 from the Comunidad de Madrid/European Union to JT and AG-P; and by a Gilead Sciences International Scholar grant in Hematology/Oncology to JR-M., Peer reviewed